|
|
| SPEAKER |
| Michael Siani-Rose |
| President and Founder |
|
Theregen Inc.
|
|
|
MEETING
|
|
May 2009 |
|
| BIOGRAPHY |
Michael Siani-Rose, President and Founder of Theregen, Inc., has more than 15 years of biotechnology experience. He has extensive expertise in the computational chemistry and drug discovery fields, and has held managerial and scientific positions at Protos/Chiron Corporation, Kosan Biosciences and Affymetrix. Michael has published 35 peer-reviewed articles, is inventor on seven patents in the field of drug discovery/drug design, and has a dozen patent applications in the fields of bioinformatics and tissue engineering. Michael received his BS degree in Chemical Engineering from the University of Rochester and has done extensive graduate work in Computer Science at University of California, San Diego.
|
| TALK |
|
|
| DESCRIPTION |
|
The purpose of the current Phase I human study (Phase I Open Label Pilot Study to Evaluate the Safety, Efficacy and Tolerability of Anginera for Adults With Left Ventricular Dysfunction AND Reversible Myocardial Ischemia Undergoing CABG Surgery) was to evaluate the safety and biological effect of using a bioresorbable scaffold-based, three-dimensional, human dermal fibroblast culture (Anginera) to treat diffuse small vessel disease in human hearts. It was hypothesised that treatment with Anginera, in conjunction with a Coronary Artery Bypass Graft (CABG) would be safe and improve ventricular performance and wall motion in these hearts after treatment. Preliminary histology data of Anginera-treated tissue confirm previously reported angiogenesis and blood vessel maturation in pre-clinical models. Additionally, echocardiography data indicate regional improvements in left ventricular function and these findings will be discussed.
|
|
